

Eugene I Hwang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4274034/publications.pdf>

Version: 2024-02-01

58
papers

1,929
citations

361413
20
h-index

315739
38
g-index

59
all docs

59
docs citations

59
times ranked

3191
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Two clinically distinct cases of infant hemispheric glioma carrying <i>ZCCHC8:ROS1</i> fusion and responding to entrectinib. <i>Neuro-Oncology</i> , 2022, 24, 1029-1031. | 1.2 | 4 |
| 2 | The current landscape of immunotherapy for pediatric brain tumors. <i>Nature Cancer</i> , 2022, 3, 11-24. | 13.2 | 21 |
| 3 | HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.. <i>Neuro-Oncology</i> , 2022, 24, i61-i62. | 1.2 | 0 |
| 4 | EPCT-05. Phase Ib study of unesbulin (PTC596) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and high-grade glioma (HGG): A report from the COllaborative Network for NEuro-Oncology Clinical Trials (CONNECT). <i>Neuro-Oncology</i> , 2022, 24, i36-i36. | 1.2 | 0 |
| 5 | IMMU-19. Outcomes of Pediatric Patients with High-Risk CNS Tumors Treated with Multi-tumor associated antigen specific T cell (TAA-T) therapy: the ReMIND trial. <i>Neuro-Oncology</i> , 2022, 24, i85-i86. | 1.2 | 1 |
| 6 | Considerations when treating high-grade pediatric glioma patients with immunotherapy. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 205-219. | 2.8 | 5 |
| 7 | A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTCâ€042). <i>Pediatric Blood and Cancer</i> , 2021, 68, e28879. | 1.5 | 24 |
| 8 | Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. <i>Acta Neuropathologica</i> , 2021, 141, 771-785. | 7.7 | 44 |
| 9 | A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. <i>Clinical Cancer Research</i> , 2021, 27, 2442-2451. | 7.0 | 13 |
| 10 | EMBR-08. CORRELATION OF HISTOPATHOLOGY, CHROMOSOMAL MICROARRAY, AND NANOSTRING BASED 22-GENE ASSAY FOR MEDULLOBLASTOMA SUBGROUP ASSIGNMENT ON â€œHEAD STARTâ€4 CLINICAL TRIAL. <i>Neuro-Oncology</i> , 2021, 23, i7-i7. | 1.2 | 0 |
| 11 | EMBR-03. PINEOBLASTOMA: A POOLED OUTCOME STUDY OF NORTH AMERICAN AND AUSTRALIAN THERAPEUTIC DATA. <i>Neuro-Oncology</i> , 2021, 23, i6-i6. | 1.2 | 0 |
| 12 | Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. <i>Neuro-Oncology</i> , 2021, 23, 1597-1611. | 1.2 | 22 |
| 13 | Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma. <i>JAMA Oncology</i> , 2021, 7, 1313. | 7.1 | 61 |
| 14 | The experience of successful treatment of <i>ETV6-NTRK3</i> -positive infant glioblastoma with entrectinib. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab022. | 0.7 | 7 |
| 15 | Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. <i>Acta Neuropathologica</i> , 2020, 139, 223-241. | 7.7 | 65 |
| 16 | Molecularly Targeted Agents in the Therapy of Pediatric Brain Tumors. <i>Paediatric Drugs</i> , 2020, 22, 45-54. | 3.1 | 7 |
| 17 | â€Np73/ETS2 complex drives glioblastoma pathogenesisâ€ targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 345-356. | 1.2 | 20 |
| 18 | Pediatric diffuse leptomeningeal glioneuronal tumor: Two clinical cases of successful targeted therapy. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28478. | 1.5 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Harmonization of postmortem donations for pediatric brain tumors and molecular characterization of diffuse midline gliomas. <i>Scientific Reports</i> , 2020, 10, 10954. | 3.3 | 7 |
| 20 | Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. <i>Neuro-Oncology</i> , 2020, 22, 773-784. | 1.2 | 44 |
| 21 | Immunotherapy Approaches for Pediatric CNS Tumors and Associated Neurotoxicity. <i>Pediatric Neurology</i> , 2020, 107, 7-15. | 2.1 | 2 |
| 22 | MBCL-16. EFFICACY OF CARBOPLATIN GIVEN CONCOMITANTLY WITH RADIATION AND ISOTRETINOIN AS A PRO-APOPTOTIC AGENT IN MAINTENANCE THERAPY IN HIGH-RISK MEDULLOBLASTOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP. <i>Neuro-Oncology</i> , 2020, 22, iii391-iii391. | 1.2 | 2 |
| 23 | EPCT-05. A PHASE I TRIAL OF THE CDK 4/6 INHIBITOR PALBOCICLIB IN PEDIATRIC PATIENTS WITH PROGRESSIVE OR REFRACTORY CNS TUMORS: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii304-iii304. | 1.2 | 0 |
| 24 | MBCL-13. CORRELATION OF HISTOPATHOLOGY, CHROMOSOMAL MICROARRAY, AND NANOSTRING BASED 22-GENE ASSAY FOR MEDULLOBLASTOMA SUBGROUP ASSIGNMENT ON "HEAD START" CLINICAL TRIAL. <i>Neuro-Oncology</i> , 2020, 22, iii390-iii390. | 1.2 | 0 |
| 25 | EPCT-16. A PHASE IB STUDY OF PTC596 IN CHILDREN WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA AND HIGH GRADE GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, iii306-iii307. | 1.2 | 0 |
| 26 | IMMU-08. reMATCH PROTOCOL: PHASE II STUDY OF EX-VIVO EXPANDED AUTOLOGOUS TUMOR SPECIFIC LYMPHOCYTE TRANSFER (X-ALT) + TOTAL TUMOR RNA DC VACCINE (TT-RNA DC) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY (MAC) AND PERIPHERAL BLOOD STEM CELL (PBSC) RESCUE OR NON-MYELOABLATIVE CHEMOTHERAPY (NMAC) AND PBSC IN PATIENTS (PTS) WITH RECURRENT PNET (R-PNET). <i>Neuro-Oncology</i> , 2020, 22, iii361-iii361. | 1.2 | 0 |
| 27 | EPCT-17. A PHASE I AND SURGICAL STUDY OF RIBOCICLIB AND EVEROLIMUS IN CHILDREN WITH RECURRENT OR REFRACTORY MALIGNANT BRAIN TUMORS: PEDIATRIC BRAIN TUMOR CONSORTIUM INTERIM REPORT. <i>Neuro-Oncology</i> , 2020, 22, iii307-iii307. | 1.2 | 0 |
| 28 | ETMR-21. META-ANALYSIS OF PINEAL REGION TUMOURS DEMONSTRATES MOLECULAR SUBGROUPS WITH DISTINCT CLINICO-PATHOLOGICAL FEATURES: A CONSENSUS STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii327-iii327. | 1.2 | 0 |
| 29 | LGG-26. DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR (DLGNT) IN CHILDREN: DIFFERENT CLINICAL PRESENTATIONS AND OUTCOMES. <i>Neuro-Oncology</i> , 2020, 22, iii371-iii371. | 1.2 | 0 |
| 30 | A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. <i>Cancer Cell</i> , 2019, 36, 51-67.e7. | 16.8 | 69 |
| 31 | Medulloblastoma rendered susceptible to NK-cell attack by TGF β 2 neutralization. <i>Journal of Translational Medicine</i> , 2019, 17, 321. | 4.4 | 32 |
| 32 | GENE-06. DISTINCT MOLECULAR SUBGROUPS OF TUMORS OF THE PINEAL REGION CORRELATE WITH CLINICAL PARAMETERS AND GENETIC ALTERATIONS. <i>Neuro-Oncology</i> , 2019, 21, ii81-ii82. | 1.2 | 0 |
| 33 | PDTM-24. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOUR CONSORTIUM. <i>Neuro-Oncology</i> , 2019, 21, vi192-vi192. | 1.2 | 0 |
| 34 | QOLP-24. PATIENTS'/PARENTS' EXPERIENCES OF RECEIVING OPTUNE DELIVERED TUMOR TREATMENT FIELDS: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY: PBTC-048. <i>Neuro-Oncology</i> , 2019, 21, vi202-vi203. | 1.2 | 1 |
| 35 | MRI Features of Histologically Diagnosed Supratentorial Primitive Neuroectodermal Tumors and Pineoblastomas in Correlation with Molecular Diagnoses and Outcomes: A Report from the Children's Oncology Group ACNS0332 Trial. <i>American Journal of Neuroradiology</i> , 2019, 40, 1796-1803. | 2.4 | 11 |
| 36 | A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26832. | 1.5 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | EPID-08. THE CURRENT LANDSCAPE OF THERAPEUTIC CLINICAL TRIALS IN PEDIATRIC BRAIN TUMORS: A REVIEW OF CLINICALTRIALS.GOV. <i>Neuro-Oncology</i> , 2018, 20, i81-i82. | 1.2 | 0 |
| 38 | Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3388-3395. | 1.6 | 58 |
| 39 | CRAN-16. IMPORTANCE OF SURGICAL INTERVENTION IN RECOVERY OF VISUAL FUNCTION IN A TEENAGER WITH AN ACIDOPHILIC STEM CELL ADENOMA. <i>Neuro-Oncology</i> , 2018, 20, i39-i40. | 1.2 | 0 |
| 40 | PDCT-07. FEASIBILITY TRIAL OF TTFIELDS (TUMOR TREATING FIELDS) FOR CHILDREN WITH RECURRENT OR PROGRESSIVE SUPRATENTORIAL HIGH-GRADE GLIOMA (HGG) AND EPENDYMOMA: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY: PBTC-048. <i>Neuro-Oncology</i> , 2018, 20, vi201-vi202. | 1.2 | 4 |
| 41 | IMMU-09. OUTCOME OF PATIENTS WITH RECURRENT DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) TREATED WITH PEMBROLIZUMAB (ANTI-PD-1): A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY (PBTC045). <i>Neuro-Oncology</i> , 2018, 20, i100-i100. | 1.2 | 11 |
| 42 | EMBR-01. MOLECULAR AND CLINICAL HETEROGENEITY IN HISTOLOGICALLY-DIAGNOSED CNS-PNET PATIENTS PROSPECTIVELY TREATED AS A SINGLE ENTITY: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP ACNS0332 TRIAL. <i>Neuro-Oncology</i> , 2018, 20, i68-i69. | 1.2 | 0 |
| 43 | EMBR-17. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOR CONSORTIUM. <i>Neuro-Oncology</i> , 2018, 20, i72-i73. | 1.2 | 0 |
| 44 | EMBR-15. DIAGNOSTIC RE-EVALUATION AND POOLED CLINICAL DATA ANALYSIS OF PATIENTS WITH PREVIOUS DIAGNOSIS OF CNS-PNET. <i>Neuro-Oncology</i> , 2018, 20, i72-i72. | 1.2 | 4 |
| 45 | Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018, 136, 227-237. | 7.7 | 86 |
| 46 | Pediatric low-grade gliomas: implications of the biologic era. <i>Neuro-Oncology</i> , 2017, 19, now209. | 1.2 | 73 |
| 47 | The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. <i>Acta Neuropathologica</i> , 2017, 133, 5-12. | 7.7 | 271 |
| 48 | Case-based review: pediatric medulloblastoma. <i>Neuro-Oncology Practice</i> , 2017, 4, 138-150. | 1.6 | 22 |
| 49 | Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. <i>Cancer Cell</i> , 2016, 30, 891-908. | 16.8 | 191 |
| 50 | Treatment of pediatric cerebral radiation necrosis: a systematic review. <i>Journal of Neuro-Oncology</i> , 2016, 130, 141-148. | 2.9 | 26 |
| 51 | Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. <i>Nature Communications</i> , 2016, 7, 11185. | 12.8 | 197 |
| 52 | Experimental Therapeutic Trial Design for Pediatric Brain Tumors. <i>Journal of Child Neurology</i> , 2016, 31, 1421-1432. | 1.4 | 0 |
| 53 | Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups. <i>Clinical Cancer Research</i> , 2015, 21, 184-192. | 7.0 | 84 |
| 54 | Handheld Optical Coherence Tomography During Sedation in Young Children With Optic Pathway Gliomas. <i>JAMA Ophthalmology</i> , 2014, 132, 265. | 2.5 | 57 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Marked Recovery of Vision in Children With Optic Pathway Gliomas Treated With Bevacizumab. JAMA Ophthalmology, 2014, 132, 111. | 2.5 | 100 |
| 56 | CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathologica, 2014, 128, 291-303. | 7.7 | 141 |
| 57 | Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatric Blood and Cancer, 2013, 60, 776-782. | 1.5 | 114 |
| 58 | Histological and molecular analysis of a progressive diffuse intrinsic pontine glioma and synchronous metastatic lesions: a case report. Oncotarget, 0, 7, 42837-42842. | 1.8 | 7 |